Complex of pectin biopolymer and acetylsalisylic acid

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to biopolymers that can find application in chemical-pharmaceutical industry, medicine and veterinary science. The complex of pectin biopolymer and acetylsalicylic acid of formula wherein R=H, Me; n=98; m=2-11, prepared by a reaction of aqueous solutions of pectin and acetylsalicylic acid under mechanic-acoustic action with weight ratio of pectin: acid=1:(0.02-0.25) and ethanol precipitation of the prepared complex.

EFFECT: complex possesses lower toxicity, lower ulcerogenic action as compared to acetylsalicylic acid and no irritant action of skin and eye mucosa.

4 cl, 1 tbl, 7 ex

 

The invention relates to a pectin biopolymers, namely pectin complexes of biopolymers with acetylsalicylic acid with low toxicity, low ulcerogenic action and no irritating to the skin and the mucous membrane of the cornea, which can find application in chemical and pharmaceutical industry, medicine and veterinary medicine.

It is well known that acetylsalicylic acid (ASA, aspirin) anti-inflammatory, antipyretic and analgesic effect, and it is widely used in fever, headache, neuralgia, in the prevention of cardiovascular diseases and atherosclerosis, as Antirheumatic agents and others (lupanova VP / Role of acetylsalicylic acid in the prevention of atherosclerosis and its complications // Russian Medical Journal. 2007. So 15. No. 16 - S-1248; Gilyarov M. / Place of acetylsalicylic acid in the international recommendations // Russian Medical Journal. 2007. So 15. No. 15 - S-1154; Kropachev Y.S. / Aspirin as a safe basis antithrombotic therapy // the Atmosphere. Cardiology. 2008. No. 1. - P.8-12; Karpov Y.A. Acetylsalicylic acid (ASA) is a key position in the primary and secondary prevention of cardiovascular diseases and their complications // Russian Medical Journal. 2008. So 16. No. 11 - S-1557; Novikova N.A., Gilyarov M. / antithrombotics therapy in acute coronary syndrome with ST segment elevation // Russian Medical Journal. 2008. So 16. No. 11 - S-1620).

The variety available dosage forms of aspirin is not possible to avoid side effects of this drug, which occur in approximately 5-10% of cases when ingested in even small doses of acetylsalicylic acid and mainly relate to changes in gastro-intestinal tract. The severity of side effects is about the same for all known forms of acetylsalicylic acid. Common dosage form of aspirin are tablets containing acetylsalicylic acid or its sodium salt in doses from 100 to 500 mg, in combination with fillers (talc, starch, calcium carbonate, and so on). Peptic ulcer and duodenal ulcers, erosive and hyperacid gastritis are the contraindications for administration of tablets of acetylsalicylic acid. With long-term use of acetylsalicylic acid can be observed not only dyspepsia and stomach bleeding, and may be affected mucous membrane of the duodenum (Barkagan SS, Kotovshikov E.F. Comparative analysis of the main and side effects of various forms of acetylsalicylic acid. Clinical pharmacology and therapy. 2004. So 13. No. 3. - P.1-4).

Given the importance of acetylsalicylic acid in clinical practice and at the same time with the place it is obecnie effects, high importance for the research on development of new dosage forms of acetylsalicylic acid with low toxicity, low ulcerogenic activity and less pronounced side effects.

To reduce the toxicity of aspirin, as well as reducing the risk of side effects by reducing therapeutic dose, it is proposed to use allyl ether ASC (EN 2382763, publ. 27.02.2010).

Known technical solutions aimed at the prevention of direct contact ASC to the mucous membrane, where the drug is immobilized on the polymer carrier. For example, the proposed composition comprising acetylsalicylic acid, biorastvorimy polymer, glucose, calcium gluconate, lipophilic and plasticizing agents (EN 2095064, publ. 10.11.1997). Known polymeric water-soluble analogue of the ASC, with more pronounced pharmacological properties and lower gastro - and nephrotoxicity, obtained by chemical immobilization ask on a copolymer of N-vinylpyrrolidone with N-(glycidyl)vinyl-γ-aminobutyric acid (RU 2201234, publ. 27.03.2003).

Pectin is a unique biologically active product of plant origin used in the food, dairy and medical industry. Due to its structural features, pectins have the ability to output the diamonds from the body of heavy metals, i.e. pectins are used as detoxicant and radioprotectors. Pectic substances possess wide spectrum of biological activity and are used in therapeutic and prophylactic purposes in the treatment of diabetes, atherosclerosis, ischemia of the heart, gastrointestinal diseases. Pectins increase the body's resistance to allergies, normalize the amount of cholesterol, are used as regulators of metabolic processes in the human body. Multifunctional pectin biopolymers can be considered as a promising reagent for the synthesis of various compounds, including pharmaceuticals (Donchenko L.V., Firsov GG / Pectin: basic properties, production and application // Moscow. Delhi. 2007. 276 S.; Minzanova ARTICLE, Mironov V.F., Konovalov A.I., mystacalis A.B., cepaea O.V., Indubai AS, Mironova G., Zobov VV / Pectins from non-traditional sources: technology, structure, properties and biological activity. Kazan : Publishing house "Printing-Service-XXI century". 2011. 224 C.).

The proposed pharmaceutical composition consisting of a mixture of aspirin and pectin (Al-Ca salt of pectin) in a weight ratio of from 1:2 to 1:15, respectively. The technical result - the slow release of the ASC and the reduction of gastrointestinal disorders (US 3485920, publ. 23.12.1969). Offered tablets drug ask for protection from lateline side effects, obtained from a mixture of aspirin, pectin (or gum) and some water (US 3946110, publ. 10.02.1975). However, the mixture of ASA and pectin does not provide sufficient uniformity that may be the cause not the correct dosing of the drug.

The objective of the invention is the expansion of the range of dosage forms of acetylsalicylic acid with reduced side effects.

The technical result - the new complexes of pectin biopolymer with acetylsalicylic acid with low toxicity, low ulcerogenic action and no irritating to the skin and the mucous membrane of the cornea compared with ASA.

The technical result is achieved with new systems pectin biopolymer with acetylsalicylic acid formula:

where R=H, Me; n=98; m=2-11,

obtained by the interaction of aqueous solutions of pectin and acetylsalicylic acid in a rotary pulsation apparatus in conditions of mechano-acoustic effects in a weight ratio of pectin: acid = 1:(0.02-0.25) and the subsequent precipitation of the complex formed with ethyl alcohol.

Presents the results obtained when using citrus pectin brand "Classic-401" production company "Herbstreith &Fox (Germany) with an average molecular mass Mn17600.

The degree polymerizes and n source of pectin calculated by the formula:

n= Mη/MG.K.,

where Mη- molecular mass source of pectin, MGK- the molecular mass of the partially balance the esterified galacturonic acid with a degree of esterification 68% (180).

The molecular weight of the original pectin determined by the method of viscosity by the equation Mark - Kuhn - Houwink linking the characteristic viscosity of the polymer in solution and its molecular weight

[η]=kMα;

where [η] is the internal or characteristic viscosity; k and α are constants that depend on the polymer structure and its interaction with the solvent. For pectin by Glikman and Orlov equation Kuhn-Mark solvent - 1% NaCl solution) as follows: (Shelukhina N.P., Abaev RS, Imuhamedov G.B. Pectin and the parameters of its receipt. Frunze: Ilim. 1987)

[η]=1.1·10-5·M1.22

In this regard, n=17600:180=98.

To confirm that binding of ASA in the complex with pectin biopolymer was a comparative study of the structure of the obtained complexes and source materials using powder diffraction x-ray diffractometer D8 Advance (Bruker). For acetylsalicylic acid on the diffraction pattern characterized by the presence of the corresponding crystalline phase distinct interference peaks for the sample of the complex observed broadened peaks that distinguish the iesa in number and position from those of pectin. In the formation of a mechanical mixture of two or more substances in the diffraction pattern observed interference peaks corresponding to all available components. Sensitivity of the method of powder diffraction to detect crystalline phase organic compounds is in the concentration range from 0.5% and above, and in the samples of complexes present from 1.67 to 10.2% ASC.

In addition, the proposed method of producing pectin complexes biopolymer with acetylsalicylic acid includes a step of deposition of the target product with ethyl alcohol followed by washing it with ethanol. It is known that acetylsalicylic acid is soluble in ethanol, so free (not bound in the complex) acetylsalicylic acid will remain in the supernatant.

The determination of ASA in the complexes of pectin - acetylsalicylic acid and determining the number m corresponding to the number of molecules ASC, bound in a complex with one molecule of pectin biopolymer, performed on the basis of methods of quantitative determination of acetylsalicylic acid (the State Pharmacopoeia of the Russian Federation, XII edition. Ed. Scientific center of expertise of medical application. 2008. S (ISBN: 978-5-9901447-1-2)), which are as follows:

Synthesized complex (weight 0.5 g) dissolved in water at 55-60°C and the titer of the Ute 0.1 N. NaOH solution until the pink colouring (indicator phenolphthalein). 1 ml of 0.1 n NaOH solution corresponds 0.01802 g ASC. In parallel titrated obtained under similar conditions the pectin sample biopolymer, not containing ASC (control sample).

The amount of acetylsalicylic acid X1%bound in the complex, is found by the formula below, determine m:

X1=(V-Vk)TK·100/a, where

V is the volume of 0.1 n NaOH solution, followed by titration of the synthesized complex, ml;

Vk- the volume of 0.1 n NaOH solution, followed by titration of the control sample, ml;

T - the title of acetylsalicylic acid (the number of the ACK corresponding to 1 ml of 0.1 n NaOH solution);

K - correction factor of 0.1 n NaOH;

and - weight complex,

Based on the obtained values of X1(number ASA %) have been recalculated for the content in the complex of acetylsalicylic acid in grams (X2), and then determine m from the formula below:

The invention is illustrated by the following examples of its implementation.

Obtaining pectin complexes biopolymer with ASC

Example 1. 10 g ASC dissolve at 55-60°C in 2000 ml of water, are added in portions with stirring to aqueous solution of 40 g of pectin in a rotary pulsation apparatus when the frequency of the treatment 1000 rpm (0.25 g acid per 1 g of pectin). The synthesis is carried out at a rotational speed of 3000 rpm for 0.5 hours at 55-60°C. the Total volume of an aqueous solution of a complex of 4.5 L. the Precipitation of the complex is carried out by adding a double volume of ethanol. The precipitate is separated, for example, by centrifugation, washed with alcohol, dried, and get complex in the form of powder light beige color. Humidity, % - 13.15%., The ash content is 0.5%.

IR spectrum, ν, cm-1); 3422 (OH), 2906 (CH), 1751, 1701, 1636 (C=O), 1192, 1102, 1046, 1017 (pyranose cycle).

The content of acetylsalicylic acid in the target product is determined by titrimetric method. Take 0.5 g of the synthesized complex was dissolved in 100 ml of water at 55-60°C and titrate with 0.1 n NaOH solution until the pink colouring (indicator phenolphthalein). Parallel to the titrated sample. The content of ASA in the complex is 10.2%, m=11, i.e. one molecule of pectin biopolymer due to the complex 11 moles of acetylsalicylic acid.

Example 2. Analogously to example 1 are complex from 0.5 g of ASA and 5 g of pectin. The content of the ASC determined by titrimetric method was 7.07%, m=7.

Example 3. Analogously to example 1 to obtain a series of 0.25 g ASC and 5 g of pectin. The content of the ASC determined by titrimetric method was 4.09%, m=4.

Example 4. Analogously to example 1 are complex from 0.1 g ASC and 5 g of pectin. The contents of ASA, certain titrimetric the named method amounted to 1.67%), m=2.

Biological tests are given for complex pectin biopolymer with ASA, where m=10.

Example 5. Determination of acute toxicity.

In experiments on laboratory mice weighing 18-22 g of the complex was administered at doses of 500, 1000, 2000, 3000 and 4000 mg/kg, equivalent to doses of acetylsalicylic acid 50, 100, 200, 300 and 400 mg/kg, respectively. Higher doses did not enter because of the inability of the preparation of solutions of a complex of more than 4%, or increase the amount of fluid administered to the animals orally. Each group was 5-6 animals. Observation of the animals was carried out for 5-6 days. Mortality was not observed in either group. Thus, in the structure of pectin complex animals tolerated dose acetylsalicylic acid 400 mg/kg of the Obtained results allow to conclude that LD50complex for mice exceeds 4000 mg/kg, i.e., more than 1.6 times higher than LD50the original ask for mice, component according to literature data 245-250 mg/kg (Brel A.K., Spasov AA, Lisin SV, Mazanova PS reinforcing prolonged antipyretic action and reduce the toxicity of salicylates. - RF patent №2382763 (2010); Greiling N., Schuler C. On the mechanism of action of salicylic acid, acetylsalicylic acid and salicylamide. // Z Rheumaforsch. - 1963. - 22. - C.47-56).

Example 6. The study irritant to skin and mucous cornea of the eye.

For ASCS is adowanie inflicted 4% solution of the complex on the shaven area of the skin and mucous membranes of the eyes of rats (group of 3 rats). The solution was applied on the skin and mucous membranes of the eyes in 2 days, 2 times a day with an interval of 2 hours and the duration of exposure to a substance from 15 to 30 minutes. Signs of irritation and any violations on the part of the skin and mucous membranes of the eyes is not revealed. Thus, the claimed complex does not have an irritating and skin-resorptive effect on the skin and mucous membranes of the eye.

Example 7. The study of chronic toxicity and ulcerogenic actions.

The study of chronic toxicity and ulcerogenic action of the complex in comparison with acetylsalicylic acid was carried out on laboratory rats weighing 350-430, Was formed 2 groups of animals 5 pieces. The rats daily for 10 days oral introduced a 0.5% solution of the ASC rate of 10 ml per kg of body weight (dose of the substance 50 mg/kg). Animals of the experimental group similarly has introduced a 5% solution of the complex (the dose of the substance is 500 mg/kg, equivalent to 50 mg/kg ASA). It was found that the period of the experiment in the control group weight loss of the animals was 24.3 g, and experienced and 17.3 g, which is 28.7% less compared with the control. This indicates the reduction of chronic toxicity of the complex in comparison with acetylsalicylic acid in the experimental group. Also investigated the weight of internal organs of animals of these groups. The results of the research the research is given in the table. The group, which has introduced the ASC, the relative weight of the liver was compared with intact animals by 22.1%, the mass of the lungs more by 10.2%, the mass of the heart is less than 17.1% and the weight of the spleen is less than 16.7% (table). These changes indicate internal system violations under the action of the ASC.

Table
Weight of internal organs of rats in % relative to the weight of the body
IndexIntact animals (normal)ASC, 50 mg/kg (control)Complex pectin with ASA, 500 mg/kg (experiment)
The weight of liver, %3,03±0,063,70±0,38 ∗∗3,55±0,15 ∗∗
The mass of the heart, %0,35±0,010,29±0,01 ∗0,34±0,01 [∗]
The weight of the spleen, %0,30±0,010,25±0,020,32±0,04
The light weight, %0,59±0,030,65±0,01 0,57±0,04

Notation: ∗ - differences from control are statistically significant at p<0,05; ∗∗ is the same, at p<0,01; without the parentheses shows the difference with the standard for intact animals, in square brackets are the differences with the control group treated with acetylsalicylic acid.

In the experimental group treated with the complex of pectin with acetylsalicylic acid, liver enlargement was less pronounced - only 17.2%. The relative weight of other organs - heart, spleen, lungs and kidneys did not differ from the mass of the same organs in intact animals (regulations). The results indicate the reduction of side effects of acetylsalicylic acid in complex with pectin compared to the original drug, respectively, on the reduction of chronic toxicity of the complex in comparison with acetylsalicylic acid.

For the study of ulcerogenic actions were conducted diagnostic autopsy stomachs of the rats of the control and experimental groups. The mucosa of the stomach in the body and the pyloric rats treated with acetylsalicylic acid at a dose of 50 mg/kg, was hyperemic, the most severe congestion in the area of the body on the lesser curvature of the stomach. Under stereomicroscope visible vascular pattern in the form of asterisks. The area of hyperemia of the mucosa of the gastric body is from 70 to 100% of the total p. the surface.

In rats treated with the complex of pectin with acetylsalicylic acid at a dose of 500 mg/kg, the mucosa of the stomach in all departments was a pale pink color, that is corresponded to the norm. Hyperemia is either not detected or detected local hyperemic areas, occupying no more than 1-3% of the mucosal surface of the body of the stomach. Under stereomicroscope vascular pattern is poorly defined, does not differ from the norm.

Thus, the inclusion of acetylsalicylic acid in complex with pectin biopolymer leads to a pronounced reduction of toxic and ulcerogenic effects of aspirin on the body. The claimed pectin complexes with acetylsalicylic acid does not possess irritant effect on skin and mucous membranes of the eye and can be used as drugs soft biological action and prolonged effect, extends the range of dosage forms of acetylsalicylic acid with reduced side effects.

1. The pectin complex biopolymer with acetylsalicylic acid formula

where R=H, Me; n=98; m=2-11,
obtained by the interaction of aqueous solutions of pectin and acetylsalicylic acid in the conditions of mechano-acoustic effects in a weight ratio of pectin:acid=1:(0.02-0.25) and precipitation of the complex formed with ethyl alcohol.

3. The complex according to claim 1, where mechano-acoustic effects is carried out in a rotary pulsation apparatus when the rotor speed of 3000 Rev/min

4. The complex according to claim 1, where mechano-acoustic effect is carried out for 30 minutes.



 

Same patents:

FIELD: food industry.

SUBSTANCE: invention relates to production of sugar beet fibres and may be used during production of a rheological properties regulator, a structure-forming gent and a thickener in food industry. The method envisages preparation of pulp from sugar beet pressure cake or chips with cellular tissue content no less than 18%, expressed pulp addition into a solution of an alkali reagent in softened water, water duty equal to 1:15-1:40, pH equal to 10-12, water temperature being 30-60°C. One performs fractional introduction of hydrogen peroxide with gradual temperature increase. The total quality of hydrogen peroxide taken is 25 kg of hydrogen peroxide with concentration equal to 30% per 50 kg of pressure cake/chips. When the temperature is 65-70°C one performs pH correction with 5-10% water alkali solution until pH is 9.0-10.0. Then one reduces temperature to 70-90°C within 20-45 minutes. Total bleaching time is 1-3 hours. Then one performs expression using a decanter centrifuge. Then pulp is washed, first - with softened water, then - with osmotic water. After each washing stage pulp is subjected to expression. Then one supplies finely dispersed ozone with further addition of 2.0-6.0% solution of Na2S2O3; one performs stirring and pulp expression using a decanter centrifuge. Then one performs repeated additional washing with further expression using a decanter centrifuge. As a result, a grainy wet product is produced.

EFFECT: production of a product wherein pectin substances are bound with a cellulose matrix which ensures good damping of fibres and a high degree of structure forming.

6 cl, 11 ex

FIELD: chemistry.

SUBSTANCE: invention relates to food industry and can be used in producing pectin from vegetable material. The method involves hydrolysis and extraction of vegetable material in an electromagnetic field, separating the solid and liquid phases, concentrating, depositing pectin and drying the pectin. Hydrolysis and extraction of the vegetable material is carried out with aqueous solution of citric acid and succinic acid at temperature of 80-90°C and pH=2 in an electromagnetic field with frequency of 25-29 Hz for 55-90 minutes. The citric acid and succinic acid are taken in ratio of 3:2, respectively. Further, the material is concentrated to pectin substance concentration of 5% and coagulated with 96% ethyl alcohol for 10 minutes. The coagulate is subjected to infrared drying in a vacuum at pressure of 0.08±0.02 MPa and temperature of 35-40°C to moisture content of the end product of not more than 7%.

EFFECT: invention increases output of pectin and increases complexing capacity thereof.

3 ex, 1 tbl

FIELD: food industry.

SUBSTANCE: method for processing silver fir wood green envisages raw material milling, the raw material treatment with an alkali solution, the raw material filtering to remove the resultant solution, acids separation by way of extraction with an organic solvent. After milling the raw material is treated with 0.1-0.5% water solution of a mineral acid at a temperature of 50±5°C with the filtered raw material subsequent two-times washing with water. Then the blended acid filtrates are concentrated by way of water boiling out in a rotor evaporator at a temperature of 60°C. Polysaccharides are sedimented from the resultant concentrate with excessive ethanol. The raw material remaining after polysaccharides extraction is subjected to treatment with an alkali and an organic solvent to separate triterpenic acids.

EFFECT: invention enables silver fir wood green processing to produce polysaccharides and triterpenic acids and to increase the target products yield.

2 ex

FIELD: food industry.

SUBSTANCE: invention relates to technical biochemistry, in particular - to determination of pectin substances quantity in vegetal raw material. "Standardised" solutions of pectin substances fractions are prepared. The fractions solutions are sampled. Saponification of pectin substances fractions in the samples of the solutions being analysed is performed with 2.5 ml of 40% NaOH solution. The pectin substances fractions are sedimented with 2.5 ml of concentrated HCl. The solutions being analysed are centrifuged in 50 ml test tubes, rotation frequency being no less than 500 rpm, during 5-7 minutes. The sediments of pectin substances fractions are suspended in distilled water in a titration cup on a magnetic stirrer for at least 30 minutes. One performs conductometric titration of the suspension of pectin substances fractions sediment, stirring. Following the conductometric titration results, graphs are drawn, relying whereon one identifies the volume of the titrant spent on pectin acid titration. Pectin substances fractions weight percentage is calculated from the formula: ω=176×0,2×V10×200×100, where 176 - pectin acid equivalent; 0.2 - titrant normality; V - titrant volume spent on pectin acid titration, ml; 200 - volume of the solution of the corresponding pectin substances fraction taken for analysis, ml; 10 - conversion to acid milliequivalents (1 ml of 0.1n NaOH corresponding to 0.1 acid milliequivalent); 100 - percentage conversion factor.

EFFECT: invention enables obtainment of accurate data with high coincidence of parallel analyses and ensures labour and time expenditures saving at all the process stages.

6 dwg, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to methods for preparing low-molecular pectin and may be used in pharmaceutical industry for preparing new therapeutic and preventive drugs, low-molecular sorbents. The method provides pectin hydrolysis in an aqueous solution of mineral acid and liquid phase separation from an insoluble residue of pectin. The low-molecular products of pectin hydrolysis are recovered from the liquid phase by settling them in an organic solvent with water. A hydrolysis feed material is low-etherified pectin of ratio max. 30%. The hydrolysis process is continuous in a continuous-flow machine. Temperature in a working chamber of the machine is maintained at 70-100°C. Feeding speed of mineral acid into the chamber is calculated by specific formula. The prepared liquid phase is neutralized to pH min. 4.0. Thereafter, the prepared liquid phase is used to settle the low-molecular products of pectin hydrolysis.

EFFECT: invention enables producing low-molecular pectin with no process loss of the feed material, substantially reducing oligogalacturonide destruction accompanying the hydrolysis process, and thereby improving the end product yield.

5 cl, 1 dwg, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to methods for preparing low-molecular pectin and may be used in pharmaceutical industry for preparing new therapeutic and preventive drugs, low-molecular sorbents. The method provides pectin hydrolysis in an aqueous solution of mineral acid with heating and liquid phase separation from an insoluble residue of pectin. The low-molecular products of pectin hydrolysis are recovered from the liquid phase by settling them in an organic solvent with water. A hydrolysis feed material is low-etherified pectin of ratio max. 30%. The hydrolysis process is continuous in a continuous-flow machine. Temperature in a working chamber of the machine is maintained at 70-100°C. Feeding speed of mineral acid into the chamber is calculated by specific formula. The prepared liquid phase is exposed to additional heat treatment in a flow heat exchange following the hydrolysis process. Temperature of the additional heat treatment process coincides with hydrolysis temperature. Heat exchange section capacity is determined by specific formula. The prepared liquid phase is neutralised to pH min. 4.0. Thereafter, the prepared liquid phase is used to settle the low-molecular products of pectin hydrolysis.

EFFECT: invention enables producing low-molecular pectin with no process loss of the feed material, substantially reducing oligogalacturonide destruction accompanying the hydrolysis process, and thereby improving the end product yield.

5 cl, 1 dwg, 4 ex

FIELD: food industry.

SUBSTANCE: invention relates to food industry. The method envisages dry beet pulp swelling in 30-40°C water at a ratio of 1:20 during 30-40 minutes. Then pulp completely swollen is squeezed and twice washed with cold water. Then the washed pulp is poured with a 0.5-2.0% enzyme preparation solution with high cellulolytic activity. The weight ratio of beet pulp and the enzyme preparation is chosen within the range of 1 :(13-15). The mixture is maintained at a temperature of 40-42°C during 1-2 hours while continuously stirred. Then the mixture is separated. One pours the produced pulp with milk whey at a ratio of 1:(13-15) and performs hydrolysis extraction during 2-2.5 hours at a temperature of 95-98°C while continuously stirring. Then one performs hydrolysate separation and filtration. Then the final product is packed.

EFFECT: invention allows to produce a food pectin beet extract with good organoleptic indices and ensure a non-waste technology of sugar beet processing.

3 ex

FIELD: food industry.

SUBSTANCE: method envisages milling coniferous trees greens. Then one extracts the tree greens with ethyl acetate and chloroform. Then remains are extracted in three stages: with distilled water, with water acidified with hydrochloric acid, with water solution of potassium hydroxide. Then one proceeds with concentration and settlement with ethyl alcohol. Then the sediment is centrifuged, dissolved in water and dialysed against distilled water. One performs lyophilic drying of the target product.

EFFECT: invention allows to produce pectin polysaccharides and glucuron- oxylan class hemicellulases of coniferous trees greens with high yield and high purification degree.

7 cl, 1 dwg, 1 tbl, 4 ex

FIELD: chemistry.

SUBSTANCE: invention relates to methods of producing low-molecular pectin. The method involves hydrolysis of pectin in aqueous solution of mineral acid while heating. Further, the liquid phase is separated from the insoluble pectin residue and neutralised to pH lower than 4.0. Low-molecular pectin hydrolysis products are extracted through precipitation thereof using a water-miscible organic solvent. After precipitation, the obtained low-molecular pectin hydrolysis products are dried. The starting material used for hydrolysis is low-etherified pectin with etherification degree of not more than 30%. Hydrolysis is carried out in cycles. The duration of one cycle is calculated using a given formula.

EFFECT: invention enables to obtain low-molecular pectin without process loss of material and also significantly ensures destruction of oligogalacturonides, thus increasing ultimate output of the product.

2 cl, 6 ex

FIELD: chemistry.

SUBSTANCE: invention relates to methods of producing low-molecular pectin. The method involves hydrolysis of pectin in aqueous solution of mineral acid while heating. Further, the liquid phase is separated from the insoluble pectin residue and neutralised to pH lower than 4.0. Low-molecular pectin hydrolysis products are extracted through precipitation thereof using a water-miscible organic solvent. After precipitation, the obtained low-molecular pectin hydrolysis products are dried. The starting material used for hydrolysis is low-etherified pectin with etherification degree of not more than 30%. Hydrolysis is carried out in cycles. The duration of one cycle is calculated using a given formula. After separation from the pectin residue, the liquid phase undergoes further hydrolysis. The duration of one cycle of additional hydrolysis is calculated using a formula.

EFFECT: invention enables to obtain low-molecular pectin without process loss of material and also significantly ensures destruction of oligogalacturonides, thus increasing ultimate output of the product.

2 cl, 6 ex

Anticancer agent // 2503450

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to an agent for treating malignant growths containing S,N-substituted derivative of isothiourea of general formula: , wherein R1=C2H5; i-C3H7; R2=C2H5; i-C3H7; The compounds are able to slow the tumour growth and to suppress the metastatic processes.

EFFECT: new agent has no undesirable side effects specific for the antiangiogenic anticancer agents with the VEGF inhibitory mechanism having the same pharmacological action.

4 cl, 4 tbl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to veterinary science and medicine. What is presented is a method of treating avian influenza A/H5N1 using high-polymer yeast RNA. A drug preparation is presented by a soapy amphiphilic one-chain high-polymer RNA of Saccharomyces cerevisiae recovered from dry baker's yeast with alkali titrated oleic acid or sodium dodecyl sulphate by treating recovered RNA in oleic acid.

EFFECT: invention provides the high-effective anti-influenza drug containing a natural interferon inducer.

1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, particularly to a method for preparing drug microcapsules of cephalosporin. The method for preparing drug microcapsules of cephalosporin consists in adding a konjak solution in carbon tetrachloride with a surfactant; a powder of cephalosporin is dissolved in water or ethanol and transferred into the konjak solution in carbon tetrachloride; once the antibiotic has formed an independent solid phase, carbinol and distilled water are added drop-by-drop; the prepared suspension of microcapsules is filtered, washed in acetone and dried; the process of microcapsules is carried out in the certain environment.

EFFECT: method provides simplifying and accelerating the process of microcapsules of water-soluble drug preparations.

7 ex

Antiherpetic agent // 2502504

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to agent possessing antiviral action, and may be used for treating herpes infections, including lip sore. The given agent contains the ingredients, wt %: a solution readily permeable through biological membranes of soapy amphiphilic complex of high-polymer RNA of Saccharomyces cerevisiae and oleic acid (as an interferon inducer) - 49.96; Vaseline oil - 20; Tween-80 - 17; Emulsifier T-2 - 13; Chlorhexidine Bigluconate - 0.04.

EFFECT: preparation shows high antiherpetic activity, good tolerability and ability to reduce a recurrence rate considerably.

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutics and represents a nutritional composition for an infant or: : a child containing lipid or fat, a protein source, a source of long-chain polysaturated fatty acids which contains docosahexaenoic acid; a supplementary calcium source to 2.5 wt % with at least 20% of the supplementary calcium source representing calcium gluconate, and PDGF-β 0.015 to 0.1 ppm (pg/mcg).

EFFECT: provided better digestibility as compared to the conventional compositions.

12 cl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to biology, preferentially to medical genetics, and describes the agent for increasing life span of Drosophila melanogaster containing ammonium pyrrolidine dithiocarbamate (PDTC). The agent is orally administered in the concentration of 20 mg/l in the course of a lifetime. The agent is not gender-specific and enables increasing the life span of both male, and female Drosophila melanogaster considerably: average (improves quality of life) and maximum (delays the ageing rate).

EFFECT: increasing the life span.

2 cl, 1 tbl, 2 dwg

FIELD: biotechnologies.

SUBSTANCE: following components are obtained: composition including inhibitor of TNF-suppressing activity Core 1 of mitochondrial breathing assembly III in a tumour cell based on nucleic acid; a member of superfamily of tumour necrosis factor (TNF); and a carrier.

EFFECT: invention allows increasing sensitivity of a tumour cell to apoptotic activity of a member of superfamily of tumour necrosis factor.

16 cl, 5 dwg, 9 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to a complex of insulin and polysaccharide, containing functional carboxyl groups, wherein the above polysaccharide is specified in polysaccharides, particularly dextran functionalised by at least one phenylalanyl derivative referred to as Phe with the above phenylalanyl derivative is specified in a group consisting of phenylalanyl or cationic alkaline salts thereof, phenylalaninol, phenylalaninamide, ethylbenzylamine, or among phenylalanine esters, and the above insulin is either human insulin, or insulin analogue. The invention also refers to a pharmaceutical composition containing at least one complex according to the invention, particularly in the form of an injection solution, as well as to the methods for preparing the pharmaceutical composition.

EFFECT: group of inventions enables the post-administration rapid insulin haemorrhage.

23 cl, 15 ex, 5 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a method for preparing interferon-coated cephalosporin microcapsules. The declared method is characterized by mixing 1% aqueous solution of human leukocyte α- or β-interferon, cephalosporin powder and preparation E472c as a surfactant. The prepared mixture is stirred until the reaction components are fully dissolved, and after a transparent solution is generated, methanol 1 ml as a first non-solvent and then isopropyl alcohol 5 ml as a second non-solvent are slowly added drop-by-drop, then filtered, washed in acetone and dried.

EFFECT: invention provides preparing the high-yield cephalosporin microcapsules and ensuring the loss reduction.

8 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to microcapsulation of cephalosporins related to β-lactam antibiotics. A method for preparing cephalosporin microcapsules is implemented by physicochemical non-solvent addition. That involves using two non-solvents that are carbinol and isopropyl alcohol taken in ratio 1:4. The microcapsule yield makes more than 90%.

EFFECT: method for cephalosporin microcapsules provides accelerating the process for preparing and simplifying the method.

3 ex

FIELD: veterinary science.

SUBSTANCE: a sow should be twice injected with oxytocin and, additionally, intramuscularly about 2-4 h after afterbirth detachment one should introduce clathroprostin at the dosage of 1 ml. The innovation suggested is very efficient in preventing metritis-mastitis-agalactia and endometritis in sows, as well.

EFFECT: higher efficiency of prophylaxis.

1 ex, 1 tbl

Up!